PERCEPTIVE ADVISORS LLC - 24 Sep 2021 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Reporting relationship: 10%+ Owner
Issuer ticker: LPTX
Reported as of: 24 Sep 2021
Net transaction value: +$9,996,489
SEC form: 4
Accepted by SEC: 28 Sep 2021, 16:21:06 UTC
Prior SEC filing: 28 Sep 2021
Next SEC filing: 30 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member

Key filing fact

PERCEPTIVE ADVISORS LLC filed Form 4 for LEAP THERAPEUTICS, INC. (LPTX) on 28 Sep 2021.

Key facts

This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for LEAP THERAPEUTICS, INC. (LPTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Sep 2021, 16:21.

Change

Previous filing in this sequence was filed on 28 Sep 2021.
Current net transaction value: +$9,996,489.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LPTX transaction Derivative

Warrants (right to buy)

Purchase

Transaction value: $9,996,489
Shares: +3,508,771
Change %
Price: $2.85
Shares after: 3,508,771
Date: 24 Sep 2021
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 3,508,771
Exercise price: $0.001000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

PERCEPTIVE ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The pre-funded warrants are immediately exercisable, provided that the warrants may not be exercised if the holder and its affiliates would beneficially own in excess of 4.99% of the Issuer's common stock outstanding after giving effect to the exercise.

Footnote F2

The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.